Sam Altman's $180M Bet on Retro Biosciences
The OpenAI chief reportedly put much of his liquid net worth into a longevity startup chasing 10 extra healthy years. Here is what the science and the money actually look like.
Sam Altman, the chief executive of OpenAI, is the sole backer behind a $180 million investment in Retro Biosciences, a startup whose stated goal is to add 10 healthy years to the average human lifespan, according to MIT Technology Review, which first reported the figure in 2023. The publication described the sum as among the largest ever put up by a single individual into a company pursuing human longevity. Altman told the outlet, “I basically just took all my liquid net worth and put it into these two companies,” referring to Retro and a nuclear-energy venture.
That bet has since grown louder. As of May 2026, Retro raised additional money at a $1.8 billion valuation, STAT reported, and the company has moved its first drug candidate into human testing. The story sits at the center of a larger shift: technology fortunes, rather than traditional pharmaceutical budgets, are increasingly funding the science of aging.
What Retro Biosciences is actually working on
Retro Biosciences was founded in 2021 by Joe Betts-LaCroix, a serial entrepreneur who previously built the small-computer maker OQO and the animal-research automation company Vium, per the company and his Wikipedia profile. The company, based near San Francisco, emerged from stealth in 2022 and runs as a multi-program shop rather than a single-drug bet.
Its work spans three areas, MIT Technology Review reported: cellular reprogramming, autophagy (the cellular process for clearing damaged components and protein aggregates), and plasma-inspired therapeutics drawn from research suggesting young blood may carry rejuvenating signals. Betts-LaCroix has framed the firm as deliberately lean. “We have no bureaucracy. I am the bureaucracy,” he told the outlet.
The autophagy program is the most advanced. Retro began its first human clinical trial in late 2025, testing a pill designed to help the body clear protein aggregates in patients with Alzheimer’s disease, STAT reported. Betts-LaCroix said in May 2026 that the trial was going well with no dose-limiting toxicities seen so far, and that data was expected around August 2026. Those are early-stage signals, not proof of an anti-aging effect, and Retro has not published peer-reviewed clinical results as of this writing.
The cellular reprogramming idea
The most ambitious thread running through Retro is cellular reprogramming, the same scientific lineage that has drawn other deep-pocketed backers. The concept traces to Shinya Yamanaka, who shared the 2012 Nobel Prize for showing that four proteins, now called Yamanaka factors (Oct4, Sox2, Klf4 and c-Myc), can reset adult cells into a flexible, embryonic-like state.
Researchers pursuing longevity are interested in partial reprogramming, the idea of dialing cells back toward a younger state without fully erasing their identity. The bet, still unproven in humans, is that this could restore youthful function to aging tissue. The approach is the founding premise of Altos Labs and its cellular reprogramming research, the $3 billion venture backed by Jeff Bezos and others, which signals how seriously investors are treating the field even before clinical validation.
The OpenAI connection: AI for protein design
What makes Altman’s involvement distinctive is the overlap with his day job. In 2025, OpenAI said it had worked with Retro’s applied AI team on GPT-4b micro, a small model adapted from GPT-4o and trained on protein sequences, biological text and structural data, according to OpenAI’s own write-up and coverage by BioPharmaTrend.
The model was pointed at two of the Yamanaka factors, Sox2 and Klf4, which are notoriously floppy and hard to engineer by conventional means. GPT-4b micro proposed redesigned variants the teams named RetroSOX and RetroKLF. In lab experiments, the companies reported, some variants showed more than a 50-fold increase in the expression of pluripotency markers, signs that cells were being reprogrammed more efficiently, along with improved DNA repair activity. The redesigns reportedly differed from the natural proteins by large stretches of amino acids, far beyond what manual tweaking typically attempts.
Those numbers come from the companies themselves and describe cell-based experiments, not human outcomes. BioPharmaTrend noted that further studies were still underway to judge whether the engineered proteins are suitable for preclinical and clinical use. Independent, peer-reviewed confirmation had not appeared as of mid-2026, so the 50-fold figure is best read as a promising internal result rather than a settled finding.
How tech-billionaire money is reshaping aging research
Altman is not alone. The longevity field has absorbed enormous private fortunes in recent years, a trend captured in our roundup of longevity founders to watch. The pattern repeats: individuals with technology wealth, comfortable with long timelines and high failure rates, are financing science that traditional drug developers have treated as too speculative.
That money buys speed and ambition, but it does not change the underlying biology or the regulatory bar. Aging is not formally recognized as a treatable disease by major regulators, which is why companies like Retro pursue specific conditions such as Alzheimer’s as their entry points. The science also remains genuinely uncertain. The clearest near-term tests of whether interventions affect human aging still run through more conventional candidates and biomarkers, the kind discussed in coverage of rapamycin, metformin and senolytics.
For now, Altman’s Retro stake functions as a high-profile wager: a bet that combining capital, a lean research culture and AI tooling can accelerate a field that has resisted easy answers. Whether it adds years to anyone’s life is a question the clinical data, not the valuation, will eventually answer.
FAQ
How much did Sam Altman invest in Retro Biosciences? MIT Technology Review reported in 2023 that Altman provided the entire $180 million behind Retro Biosciences, making him the company’s sole backer at the time. He described it as roughly his full liquid net worth split between Retro and one other venture.
What is the OpenAI and Retro Biosciences GPT-4b collaboration? OpenAI and Retro’s AI team developed GPT-4b micro, a protein-engineering model that proposed redesigned versions of two Yamanaka reprogramming factors. The companies reported large gains in lab measures of cell reprogramming, though the results are preliminary and not yet independently peer-reviewed.
Has Retro Biosciences proven it can extend human lifespan? No. Retro’s goal is to add 10 healthy years, but its most advanced program is an early human trial in Alzheimer’s disease, with data expected around August 2026. No anti-aging effect in people has been demonstrated. This article is journalism, not medical advice.
Sources
- MIT Technology Review: Sam Altman invested $180 million into a company trying to delay death
- STAT: Longevity startup Retro Biosciences says latest fundraising values it at $1.8 billion
- OpenAI: Accelerating life sciences research with Retro Biosciences
- BioPharmaTrend: OpenAI and Retro Biosciences report 50x pluripotency marker expression gains
- Wikipedia: Joe Betts-LaCroix
Sam Altman Retro Biosciences longevity cellular reprogramming OpenAI aging research biotech funding Yamanaka factors
